-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, GsGqWcXmnDpVnC/+p+1tySoiuogQU4lTTz/PX0TltcIHU+KVZKdGeEucuFmDgbuc BvvDoLtSF0R5OmJkW4/tzg== 0001144204-08-008650.txt : 20080331 0001144204-08-008650.hdr.sgml : 20080331 20080213172111 ACCESSION NUMBER: 0001144204-08-008650 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20080213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Forticell BioScience, Inc. CENTRAL INDEX KEY: 0000889992 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 113068704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 3960 BROADWAY STREET 2: BLDG 28 CITY: NEW YORK STATE: NY ZIP: 10032 BUSINESS PHONE: (212) 740-6999 MAIL ADDRESS: STREET 1: 3960 BROADWAY, CITY: NEW YORK STATE: NY ZIP: 10032 FORMER COMPANY: FORMER CONFORMED NAME: ORTEC INTERNATIONAL INC DATE OF NAME CHANGE: 19950822 CORRESP 1 filename1.htm
Forticell Bioscience, Inc.
3960 Broadway
New York, NY 10032
Tel: (212) 740-6999
Fax: (212) 740-2570

February 13, 2008

U.S. Securities & Exchange Commission
Division of Corporate Finance
M.S. 6010
Washington, DC 20549
 
Attn:  Russell Mancuso, Branch Chief
     
 
RE:
Forticell Bioscience, Inc. (formerly known as Ortec International, Inc.)
   
Amended Registration Statement on Form S-1
   
File No. 333-146142

Gentlepersons:

This letter shall serve as the request of Forticell Bioscience, Inc., pursuant to Rule 461, to accelerate the effective date of the above-referenced registration statement to Thursday, February 14, 2008, 3:00PM EST, or as soon as practicable thereafter. We are aware of our filing obligations under the Securities Act of 1933, as amended, and intend to fully comply therewith.

We also make the following representations:
 
 
*
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
 
 
*
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
 
 
*
the company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Thank you very much for your kind cooperation and assistance in this matter.

Very truly yours,


/s/ Alan W. Schoenbart 
Alan W. Schoenbart
Chief Financial Officer
 -----END PRIVACY-ENHANCED MESSAGE-----